Studies on the Influence of Long-Acting Insulin Analogs on Cancer Risk Should Be Based on the New-User Design Only

J Clin Oncol. 2018 Mar 10;36(8):829-830. doi: 10.1200/JCO.2017.76.8721. Epub 2018 Jan 25.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Breast Neoplasms*
  • Diabetes Mellitus, Type 2*
  • Female
  • Humans
  • Hypoglycemic Agents
  • Incidence
  • Insulin, Long-Acting

Substances

  • Hypoglycemic Agents
  • Insulin, Long-Acting